Abstract
Background:
The tumorigenesis of lung cancer is complicated, and genetic factor may have the role in the malignant transformation of lung cells. IL-10 gene polymorphisms have been evaluated for their potential roles in lung cancer. However, those studies results are controversial. To clarify the effects of IL-10 rs1800871, rs1800872 and rs1800896 polymorphisms on the risk of lung cancer, a meta-analysis was performed with eligible individual studies.
Methods:
Eligible publications were gathered by retrieving PubMed, Web of Science, Embase, Wan Fang, and CNKI up to September 01, 2023. The pooled odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of such association.
Results:
A total of 23 studies, including 5950 patients with lung cancer and 8046 healthy controls, were identified in this meta-analysis. Overall, there was no a significant association between the rs1800871, rs1800872 and rs1800896 polymorphisms at IL-10 gene and susceptibility to lung cancer globally when all studies in the pooled into this meta-analysis. Stratified analysis by ethnicity showed that rs1800872 polymorphism was associated with lung cancer among Asians and Caucasians. However, no significant association was identified between the rs1800871 and rs1800896 and risk of lung cancer.
Conclusions:
Pooled data showed that IL-10 rs1800871, rs1800872 and rs1800896 polymorphisms were not associated with lung cancer globally. Future well-designed large case-control studies with different ethnicities are recommended.
Key Words: Interleukin 10, Polymorphism, Lung neoplasms, Meta-analysis
Introduction
Lung cancer is one of the most common types of human cancer, and it is additionally one of the leading causes of cancer associated mortality globally [1-3]. A meta-analysis revealed a statistically significant increase in mortality rate in lung cancer patients compared with other patients with cancer [4, 5]. It is estimated that Lung cancer remained the leading cause of cancer death and was responsible for 1.8 million deaths, or 18% of all deaths due to cancer in 2020 globally [6, 7]. However, it is noted that women were less than half as likely to die of lung cancer as men [6, 8]. Lung cancer is the most frequently occurring cancer and the leading cause of cancer death in men, followed by prostate and colorectal cancer for incidence and liver and colorectal cancer for mortality. According to the latest GLOBOCAN estimates, lung cancer ranks first (39 per 100,000) and prostate cancer ranks second (37.5 per 100,000) in higher HDI countries, and vice versa for lower HDI countries (11.3 per 100,000 for prostate cancer and 10.3 per 100,000 for lung cancer) [7, 9]. Lung cancer is categorized into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC, which constitutes ~80% of all lung cancers, is further classified into three major pathologic subtypes: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma [10-12].
Genetic susceptibility to lung cancer occurs mainly through rare germline pathogenic variants specifically associated with cancer risk [13-15]. Smoking and air pollution are the major causes of lung cancer; however, numerous studies have demonstrated that genetic factors also contribute to the development of lung cancer [16-18]. A decade after the first genome-wide association study (GWAS) published for of lung cancer was published approximately 45 genomic loci has now been significantly associated with lung cancer risk. These include the 5p15 locus (telomerase reverse transcriptase), the 6p21 locus (regulates G-protein signaling), and the 15q25-26 loci, which have been shown to increase nicotine dependence and lung cancer susceptibility [19, 20].
The biological significance of IL-10 is extensive and diverse because of its role in many diseases [21-23]. IL-10 is known to play a substantial role in inflammation and immune processes [24]. IL-10 has been reported to inhibit the production of proinflammatory cytokines tumor necrosis factor alpha (TNFα), interleukin 1α and β (IL1α and β), interleukin IL-6 (IL-6), and interleukin-8 (IL-8), while stimulating B-cell proliferations, differentiation, and production [25-29]. IL-10 is an immunomodulatory cytokine encoded by the IL-10 gene on chromosome 1q31-32, containing five exons separated by four introns, and its receptor is located on chromosome 11 [30-32]. Polymorphisms located in the 5′-flanking region of the IL-10 gene are known to be involved in regulating the production of IL-10 [33, 24]. Among the cancer susceptibility studies, rs1800871 (-819C>T), rs1800872 (-592C>A) and rs1800896 (-1082A>G) polymorphisms are the most widely studied mutation point [34]. The promoter region polymorphisms of IL-10 gene has been associated with susceptibility to several cancers including lung cancer [35, 36, 13, 37]. Many studies have reported the relationship between race and IL-10 gene polymorphism and lung cancer risk in recent years. Zhang et al., reported a significant association of the IL-10 rs1800871 and rs1800872 polymorphisms with lung cancer in a Chinese population [38], while Hsia et al., have reported that the IL-10 rs1800871 polymorphism may have a protective effect on lung cancer risk among Taiwanese population [39]. Therefore, to estimate the effect of the rs1800871, rs1800872 and rs1800896 polymorphisms at IL-10 gene with lung cancer risk, as well as to quantify the potential between-study heterogeneity, we performed this meta-analysis based on published case-control studies.
Materials and Methods
Search strategies
The ethical approval was not required for this study, as it is a systematic review and meta-analysis. This work was conducted according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. The identification and selection of articles were performed in the databases Science Direct, the National Library of Medicine National Institutes of Health of the USA (PUBMED), PubMed, EMBASE, Wed of Science, Elsevier, Google Scholar, Cochrane Library, SciELO, SID, WanFang, VIP, Chinese Biomedical Database (CBD) and Chinese National Knowledge Infrastructure (CNKI) to identify all relevant studies on the association of IL-10 rs1800871 (-819C>T), rs1800872 (-592C>A) and rs1800896 (-1082A>G) polymorphisms with risk of lung cancer. The time cutoff was designated from the beginning of publications on the rs1800871, rs1800872 and rs1800896 polymorphisms until September 01, 2023. Combinations of the following MeSH terms and keywords were used in the search: (‘’lung carcinomas’’ or ‘’lung adenocarcinoma’’ or ‘’lung cancer’’ or ‘’small cell lung cancer’’ or ‘’Non-Small Cell Lung Cancer’’) and (‘’-1082 G>A’’ or ‘’rs1800896’’ or ‘’-819 T>C’’ or ‘’rs1800871’’ or ‘’-592A>C’’ or ‘’rs1800872’’) AND (‘’Gene’’ OR ‘’Single-Nucleotide Polymorphism” or “SNP” OR ‘’Polymorphism’’ OR ‘’Genotype’ OR ‘’Allele’’ OR ‘’Variation’’ OR ‘’Mutation’’). The search was limited to human studies published in English and Chinese language. We also reviewed the references list of relevant reviews and eligible publications to find other potentially sources.
Inclusion and exclusion criteria
Studies meeting the following criteria were included: 1) it was published by September 01, 2023; 2) studies with case-control or cohort design; 3) studies evaluated association of IL-10 rs1800871, rs1800872 and rs1800896 polymorphisms with lung cancer; 4) studies with available and sufficient data for calculating an odds ratio (OR) with 95% confidence interval (CI). The following exclusion criteria were also used: 1) papers do not involve human subjects; 2) studies with in sufficient data on genotype frequencies; 3) unrelated to each of lung cancer and IL-10 polymorphisms; 4) studies involving family members (including sibling, twins and trios-parents studies), because their analysis was based on linkage considerations; 5) abstracts, case reports, commentaries, editorials, conference articles, reviews, proceedings and meta-analyses; and 6) duplicates or overlapping studies. If more than one study was published by the same author(s) using repeated or overlapped data, the studies with the largest sample size or the most recently published study was included to the meta-analysis.
Data extraction
Two independent investigators who were co-authors of this meta-analysis were selected to screen the search results. After they found relevant publications, they searched the full text of those studies, read them carefully, and evaluated them to decide whether to include or exclude them. The whole process was done by two investigators independently. If there was any disagreement over whether to include an article, they would discuss it with a third reviewer to decide whether to include the article. We sought the following data from each study: first author’s name, year of publication, ethnicity of each study population, country, source of controls, genotyping method, number of cases and controls, as well as numbers of cases and controls for IL-10 polymorphisms, minor allele frequency (MAF) in healthy subjects, and evidence of Hardy-Weinberg equilibrium (HWE).
Quality Score Assessment
The Newcastle-Ottawa Score (NOS) were performed to assess the quality of included studies in the meta-analysis and to assess the various aspects of the methodology used by the observational research, which are relevant to the quality of the study. This standard assessed 3 sections (selection of cases, comparability of groups, and determination of exposure) and 8 items. In the selection and exposure categories, a quality research item received 1 star, and a comparable category could receive at most 2 stars. The quality assessment values ranged from 0 stars (worst) to 9 stars (best), and studies with a score ≥7 were defined as high quality. Generally, the study which scored at least 5 points was considered to be included in meta-analysis and any discrepant opinions were resolved by discussion and consensus.
Statistical Analysis
The strength of the association between IL-10 rs1800871, rs1800872 and rs1800896 polymorphisms and lung cancer risk was estimated by odds ratio (OR) with the corresponding 95% confidence intervals (CIs). The significance of pooled ORs was tested by Z-test, in which P<0.05 was considered significant. The association of IL-10 rs1800871 (-819C>T), rs1800872 (-592C>A) and rs1800896 (-1082A>G) polymorphisms was estimated under five genetic models, i.e., allele (B vs. A), homozygote (BB vs. AA), heterozygote (BA vs. AA), dominant (BB+BA vs. AA), and recessive (BB vs. BA+AA), which a ‘‘A’’ denotes a major allele; ‘‘B’’ denotes a minor allele. The chi-square test was used to evaluate the between-study heterogeneity. If P <0.10, it was considered to have significant heterogeneity in statistics [40, 41]. Moreover, I2 test to quantify the heterogeneity, which ranges from 0 to 100% and represents the proportion of between-study variability attributable to heterogeneity rather than chance (I2<25%, no heterogeneity; I2 25-50%, moderate heterogeneity; I2>50%, large or extreme heterogeneity) [42, 43]. When significant heterogeneity existed, we selected a random-effects model (the DerSimonian and Laird method) for statistics. Otherwise, the fixed-effects model (the Mantel-Haenszel method) was used [44, 35, 45, 41, 46]. The Hardy-Weinberg equilibrium (HWE) of the controls was evaluated by Fisher exact test and a p-value less than 0.05 was considered as significant disequilibrium (HWE-violating) [47-49]. Subgroup analyses by ethnicity, country, source of controls, and genotyping methods were performed to explore the potential sources of between-study heterogeneity in the meta-analysis [50, 33, 51]. One-way sensitivity analysis, by which a single study in the meta-analysis was omitted each time to reflect the influence of the individual data set for the pooled OR, was carried out to assess the stability of the results [31, 52, 53]. Moreover, sensitivity analysis was performed by excluding HWE-violating studies. To assess the potential influences of the publication bias on the results, Begg’s funnel plots were generated. An asymmetrical plot usually indicates the existence of the publication bias [54-56]. Moreover, Egger’s linear regression test which measures funnel plot asymmetry using a natural logarithm scale of OR was performed to evaluate the symmetry of the plot. All statistical tests were performed using Comprehensive Meta-Analysis (CMA) version 2.0 software (Biostat, USA). All P values in the meta-analysis were 2-sided, and P values less than 0.05 were considered significant.
Results
Characteristics of the Included Studies
The corresponding characteristics were seen in Table 1. The flow chart of literature search and study selection was illuminated in Figure 1. After a comprehensive literatures search we have identified 612 articles. Among them, 252 were excluded based on titles and abstracts. The full texts of the remaining 119 articles were screened and 69 studies were excluded based on inclusion and exclusion criteria. Finally, a total of 23 case-control studies in 12 publications [57-63, 39, 38, 64-66] on 5950 patients with lung cancer and 8046 healthy controls were included in the meta-analysis. The details of each study were shown in Table 1. Of those studies, six case-control studies [57, 58, 39, 38, 65] with 1543 cases and 2175 controls were on rs1800871, eight case-control studies [58-60, 62, 63, 39, 38, 65] with 2410 cases and 3234 controls on rs1800872, and nine case-control studies [57, 58, 60, 61, 63, 39, 64-66] with 1997 cases and 2637 controls on the rs1800896. The publication year of studies ranged from 2005 to 2018. Among the included studies, 12 were preformed among the Asians and eleven among the Caucasians. The countries of these studies included Germany, Taiwan, Turkey, China, United States, Denmark, Norway and India. The genotypes in the healthy control group for four studies were not consistent with HWE (P < 0.05).
Table 1.
Characteristics of the Studies Included in Meta-Analysis
| First Author/Year | Ethnicity (Country) |
Type | SOC | Genotyping Methods |
Case/Control | Patients | Healthy Control | MAFs | HWE | NOS | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genotypes | Alleles | Genotypes | Alleles | |||||||||||||||
| rs1800871 | TT | TC | CC | T | C | TT | TC | CC | T | C | ||||||||
| Seifart 2005 | Germany(Caucasian) | NSCLC | HB | PCR-RFLP | 40/242 | 24 | 14 | 2 | 62 | 18 | 140 | 88 | 14 | 368 | 116 | 0.76 | 0.972 | 7 |
| Shih 2005 | Taiwan(Asian) | NSCLC | HB | PCR-RFLP | 154/205 | 66 | 58 | 30 | 190 | 118 | 104 | 86 | 15 | 294 | 116 | 0.283 | 0.627 | 7 |
| Colakogullari 2008 | Turkey(Caucasian) | LC | HB | PCR-SSP | 44/59 | 19 | 23 | 2 | 61 | 27 | 26 | 26 | 7 | 78 | 40 | 0.661 | 0.898 | 7 |
| Hsia 2014 | Taiwan(Asian) | LC | HB | PCR-RFLP | 358/716 | 212 | 128 | 18 | 552 | 164 | 372 | 265 | 79 | 1009 | 423 | 0.295 | 0.003 | 7 |
| Zhang 2015 | China(Asian) | LC | HB | PCR-RFLP | 330/336 | 108 | 135 | 87 | 351 | 309 | 145 | 144 | 47 | 434 | 238 | 0.354 | 0.246 | 8 |
| Eaton 2018 | USA(Caucasian) | LC | PB | TaqMan | 617/617 | 382 | 195 | 40 | 959 | 275 | 371 | 206 | 40 | 948 | 286 | 0.232 | 0.121 | 8 |
| rs1800872 | AA | AC | CC | A | C | AA | AC | CC | A | C | ||||||||
| Shih 2005 | Taiwan(Asian) | NSCLC | HB | PCR-RFLP | 154/205 | 66 | 70 | 18 | 202 | 106 | 116 | 76 | 13 | 308 | 102 | 0.249 | 0.907 | 7 |
| Colakogullari 2008 | Turkey(Caucasian) | LC | HB | PCR-SSP | 44/59 | 19 | 23 | 2 | 61 | 27 | 27 | 25 | 7 | 79 | 39 | 0.669 | 0.743 | 7 |
| Vogel 2008 | Denmark(Caucasian) | LC | HB | PCR | 403/744 | 241 | 149 | 13 | 631 | 175 | 452 | 250 | 42 | 1154 | 334 | 0.776 | 0.341 | 8 |
| Liang 2011 | China(Asian) | LC | HB | PCR-RFLP | 116/120 | 69 | 36 | 11 | 174 | 58 | 69 | 44 | 7 | 182 | 58 | 0.242 | 0.996 | 7 |
| Hart 2011 | Norway(Caucasian) | NSCLC | HB | TaqMan | 434/433 | 243 | 175 | 15 | 661 | 205 | 264 | 144 | 26 | 672 | 196 | 0.774 | 0.287 | 8 |
| Hsia 2014 | Taiwan(Asian) | LC | HB | PCR-RFLP | 358/716 | 173 | 145 | 40 | 491 | 225 | 368 | 277 | 71 | 1013 | 419 | 0.293 | 0.079 | 7 |
| Zhang 2015 | China(Asian) | LC | HB | PCR-RFLP | 330/336 | 110 | 156 | 64 | 376 | 284 | 75 | 176 | 85 | 326 | 346 | 0.485 | 0.373 | 8 |
| Eaton 2018 | USA(Caucasian) | LC | PB | TaqMan | 572/620 | 382 | 175 | 15 | 939 | 205 | 375 | 206 | 39 | 956 | 284 | 0.229 | 0.14 | 8 |
| rs1800896 | AA | AG | GG | A | G | AA | AG | GG | A | G | ||||||||
| Seifart 2005 | Germany(Caucasian) | NSCLC | HB | PCR-RFLP | 39/243 | 6 | 21 | 12 | 33 | 45 | 86 | 115 | 42 | 287 | 199 | 0.409 | 0.738 | 7 |
| Shih 2005 | Taiwan(Asian) | NSCLC | HB | PCR-RFLP | 154/205 | 115 | 39 | 0 | 269 | 39 | 194 | 11 | 0 | 399 | 11 | 0.027 | 0.693 | 7 |
| Colakogullari 2008 | Turkey(Caucasian) | LC | HB | PCR-SSP | 44/59 | 11 | 30 | 3 | 52 | 36 | 33 | 21 | 5 | 87 | 31 | 0.263 | 0.532 | 7 |
| Hao 2009 | China(Asian) | LC | PB | TaqMan | 43/52 | 36 | 7 | 0 | 79 | 7 | 46 | 6 | 0 | 98 | 6 | 0.066 | 0.606 | 7 |
| Hart 2011 | Norway(Caucasian) | NSCLC | HB | TaqMan | 436/435 | 120 | 207 | 109 | 447 | 425 | 104 | 226 | 105 | 434 | 436 | 0.501 | 0.414 | 8 |
| Hsia 2014 | Taiwan(Asian) | LC | HB | PCR-RFLP | 358/716 | 273 | 69 | 16 | 615 | 101 | 561 | 130 | 25 | 1252 | 180 | 0.126 | ≤0.001 | 7 |
| Peddireddy 2016 | India(Asian) | NSCLC | HB | PCR-RFLP | 246/250 | 156 | 69 | 21 | 381 | 111 | 130 | 84 | 36 | 344 | 156 | 0.312 | ≤0.001 | 8 |
| Eaton 2018 | USA(Caucasian) | LC | PB | TaqMan | 595/595 | 162 | 273 | 160 | 597 | 593 | 140 | 297 | 158 | 577 | 613 | 0.515 | 0.985 | 8 |
| Nong 2018 | China(Asian) | LC | HB | NA | 82/82 | 28 | 29 | 25 | 85 | 79 | 28 | 26 | 28 | 82 | 82 | 0.5 | ≤0.001 | 8 |
NSCLC, Non-Small Cell Lung Carcinoma; LC,lung cancer; SOC, Source of Controls, HB, Hospital Based; PB, Population Based ; PCR-RFLP, Restriction Fragment Length Polymorphism; HWE, Hardy-Weinberg equilibrium; MAF, Minor Allele Frequency; NOS, Newcastle-Ottawa Scale.
Figure 1.
Flow Diagram of the Study Selection Process
Quantitative Synthesis
The summary of the meta-analysis of the association between IL-10 rs1800871, rs1800872 and rs1800896 polymorphisms and susceptibility to lung cancer risk were listed in Tables 2-4. Pooled data showed that there was no a significant association between IL-10 rs1800871, rs1800872 and rs1800896 polymorphisms and lung cancer risk under all five genetic models in overall population worldwide (Figure 2). Stratified analysis by ethnicity revealed that the IL-10 rs1800872 polymorphism was associated with lung cancer risk in Asians under four genetic models, i.e., allele (C vs. A: OR= 1.261, 95% CI 1.112-1.430, p≤0.001), homozygote (CC vs. AA: OR= 1.615, 95% CI 1.229-2.214, p=0.001), dominant (CC+CA vs. AA: OR= 0.658, 95% CI 0.517-0.837, p=0.001), and recessive (CC vs. CA+AA: OR= 1.521, 95% CI 1.195-1.935, p=0.001), and Caucasians under the recessive model (CC vs. CA+AA: OR= 0.837, 95% CI 0.706-0.993, p=0.041, Table 3). However, stratified analysis by ethnicity also revealed that there was not a significant association between rs1800871 and rs1800896 polymorphisms of IL-10 gene and lung cancer among Asians and Caucasians (Tables 2, 4).
Table 2.
Summary Risk Estimates for association between IL-10 rs1800871 Polymorphism and Risk of Lung Cancer
| Subgroup | Genetic Model | Type of Model | Heterogeneity | Odds Ratio (OR) | Publication Bias | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| I2 (%) | PH | OR | 95% CI | ZOR | POR | PBeggs | PEggers | |||
| Overall | T vs. C | Random | 86.14 | ≤0.001 | 1.067 | 0.780-1.460 | 0.406 | 0.685 | 1 | 0.875 |
| TT vs. CC | Random | 58.17 | 0.026 | 0.997 | 0.700-1.420 | -0.017 | 0.987 | 0.133 | 0.267 | |
| TC vs. CC | Fixed | 0 | 0.575 | 0.973 | 0.842-1.125 | -0.369 | 0.712 | 0.452 | 0.4 | |
| TT+TC vs. CC | Random | 85.46 | ≤0.001 | 0.922 | 0.458-1.852 | -0.229 | 0.819 | 0.452 | 0.608 | |
| TT vs. TC+CC | Random | 85.46 | ≤0.001 | 1.085 | 0.540-2.181 | 0.229 | 0.819 | 0.452 | 0.608 | |
| Asians | T vs. C | Random | 94 | ≤0.001 | 1.208 | 0.682-2.140 | 0.647 | 0.518 | 1 | 0.651 |
| TT vs. CC | Random | 93.88 | ≤0.001 | 1.455 | 0.407-5.200 | 0.576 | 0.564 | 1 | 0.964 | |
| TC vs. CC | Fixed | 38.35 | 0.197 | 1 | 0.825-1.211 | -0.003 | 0.997 | 1 | 0.585 | |
| TT+TC vs. CC | Random | 93.29 | ≤0.001 | 0.706 | 0.222-2.243 | -0.59 | 0.555 | 1 | 0.913 | |
| TT vs. TC+CC | Random | 93.29 | ≤0.001 | 1.416 | 0.446-4.495 | 0.59 | 0.555 | 1 | 0.913 | |
| Caucasians | T vs. C | Fixed | 0 | 0.952 | 0.94 | 0.792-1.116 | -0.707 | 0.48 | 0.296 | 0.306 |
| TT vs. CC | Fixed | 0 | 0.588 | 0.905 | 0.590-1.387 | -0.458 | 0.647 | 0.296 | 0.394 | |
| TC vs. CC | Fixed | 0 | 0.817 | 0.939 | 0.753-1.171 | -0.559 | 0.576 | 0.296 | 0.477 | |
| TT+TC vs. CC | Fixed | 0 | 0.479 | 1.085 | 0.713-1.650 | 0.379 | 0.705 | 0.296 | 0.413 | |
| TT vs. TC+CC | Fixed | 0 | 0.479 | 0.922 | 0.606-1.403 | -0.379 | 0.705 | 0.296 | 0.413 | |
Table 4.
Summary Risk Estimates for Association between IL-10 rs1800896 Polymorphism and Risk of Lung Cancer
| Subgroup | Genetic Model | Type of Model | Heterogeneity | Odds Ratio (OR) | Publication Bias | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| I2 (%) | PH | OR | 95% CI | ZOR | POR | PBeggs | PEggers | |||
| Overall | G vs. A | Random | 82.85 | ≤0.001 | 1.232 | 0.941-1.613 | 1.516 | 0.13 | 0.076 | 0.073 |
| GG vs. AA | Random | 71.79 | ≤0.001 | 1.151 | 0.637-2.084 | 0.464 | 0.641 | 0.133 | 0.267 | |
| GA vs. AA | Random | 83.28 | ≤0.001 | 1.394 | 0.926-2.098 | 1.592 | 0.111 | 0.175 | 0.03 | |
| GG+GA vs. AA | Fixed | 33.17 | 0.175 | 0.989 | 0.837-1.170 | -0.125 | 0.9 | 0.763 | 0.982 | |
| GG vs. GA+AA | Fixed | 33.17 | 0.175 | 1.011 | 0.855-1.195 | 0.125 | 0.9 | 0.763 | 0.982 | |
| Asians | G vs. A | Random | 87.98 | ≤0.001 | 1.296 | 0.743-2.260 | 0.913 | 0.361 | 0.806 | 0.329 |
| GG vs. AA | Fixed | 61.1 | 0.076 | 0.794 | 0.545-1.156 | -1.206 | 0.228 | 1 | 0.651 | |
| GA vs. AA | Random | 85.59 | ≤0.001 | 1.435 | 0.739-2.789 | 1.066 | 0.286 | 1 | 0.396 | |
| GG+GA vs. AA | Fixed | 46.74 | 0.153 | 1.223 | 0.856-1.748 | 1.104 | 0.269 | 1 | 0.404 | |
| GG vs. GA+AA | Fixed | 46.74 | 0.153 | 0.832 | 0.509-1.359 | -0.735 | 0.462 | 1 | 0.404 | |
| Caucasians | G vs. A | Random | 77.5 | 0.004 | 1.207 | 0.894-1.628 | 1.23 | 0.219 | 0.308 | 0.017 |
| GG vs. AA | Random | 64.34 | 0.038 | 1.187 | 0.721-1.955 | 0.675 | 0.5 | 0.308 | 0.167 | |
| GA vs. AA | Random | 83.54 | ≤0.001 | 1.372 | 0.754-2.498 | 1.035 | 0.301 | 0.308 | 0.033 | |
| GG+GA vs. AA | Fixed | 14.03 | 0.322 | 0.932 | 0.771-1.126 | -0.728 | 0.467 | 0.734 | 0.567 | |
| GG vs. GA+AA | Fixed | 14.03 | 0.322 | 1.073 | 0.888-1.297 | 0.728 | 0.467 | 0.734 | 0.567 | |
Figure 2.
Forest Plots for the Association of IL-10 Polymorphism with Lung Cancer Risk. A: rs1800871 (allele model: T vs. C); B: rs1800872 (homozygote model: CC vs. AA) ; and C: rs1800896 (heterozygote model: GA vs. AA)
Table 3.
Summary Risk Estimates for association between IL-10 rs1800872 Polymorphism and Risk of Lung Cancer
| Subgroup | Genetic Model | Type of Model | Heterogeneity | Odds Ratio (OR) | Publication Bias | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| I2 (%) | PH | OR | 95% CI | ZOR | POR | PBeggs | PEggers | |||
| Overall | C vs. A | Random | 73.62 | ≤0.001 | 1.083 | 0.906-1.294 | 0.874 | 0.382 | 0.71 | 0.55 |
| CC vs. AA | Random | 69.86 | 0.002 | 1.393 | 0.908-2.138 | 1.517 | 0.129 | 0.901 | 0.785 | |
| CA vs. AA | Random | 58.72 | 0.018 | 1.228 | 0.955-1.578 | 1.603 | 0.109 | 0.107 | 0.05 | |
| CC+CA vs. AA | Random | 72.12 | 0.001 | 0.949 | 0.703-1.281 | -0.34 | 0.733 | 0.71 | 0.765 | |
| CC vs. CA+AA | Random | 72.6 | 0.001 | 1.05 | 0.776-1.421 | 0.318 | 0.751 | 0.71 | 0.755 | |
| Asians | C vs. A | Fixed | 43.73 | 0.149 | 1.261 | 1.112-1.430 | 3.61 | ≤0.001 | 0.734 | 0.86 |
| CC vs. AA | Fixed | 17.91 | 0.301 | 1.615 | 1.229-2.214 | 3.435 | 0.001 | 0.734 | 0.635 | |
| CA vs. AA | Fixed | 20.93 | 0.285 | 1.164 | 0.965-1.403 | 1.589 | 0.112 | 1 | 0.95 | |
| CC+CA vs. AA | Fixed | 0.00 | 0.402 | 0.658 | 0.517-0.837 | -3.41 | 0.001 | 0.734 | 0.786 | |
| CC vs. CA+AA | Fixed | 0.00 | 0.402 | 1.521 | 1.195-1.935 | 3.41 | 0.001 | 0.734 | 0.786 | |
| Caucasians | C vs. A | Fixed | 53.99 | 0.089 | 0.899 | 0.798-1.012 | -1.758 | 0.079 | 0.734 | 0.661 |
| CC vs. AA | Fixed | 80.66 | 0.001 | 1.016 | 0.709-1.454 | 0.084 | 0.933 | 1 | 0.655 | |
| CA vs. AA | Fixed | 75.92 | 0.006 | 1.029 | 0.806-2.989 | 1.315 | 0.188 | 0.734 | 0.077 | |
| CC+CA vs. AA | Fixed | 56.33 | 0.076 | 1.186 | 1.000-1.406 | 1.955 | 0.051 | 0.452 | 0.608 | |
| CC vs. CA+AA | Fixed | 56.60 | 0.075 | 0.837 | 0.706-0.993 | -2.042 | 0.041 | 0.734 | 0.406 | |
Sensitivity Analysis
Meta-analyses were performed repeatedly when each eligible study had been removed. The results indicated that fixed-effects estimates and/or random-effects estimates before and after the omission of each study were similar at large for each gene model, suggesting high stability of our pooled results. Moreover, we conducted sensitivity analysis to detect the influence of each study on the pooled OR by deleting the single study and by deleting those studies did not accordance with HWE. After excluding several studies inconsistent with HWE, we did not found substantial alteration under all five genetic models.
Heterogeneity test
Based on the generalized results found for this meta-analysis, a high level of heterogeneity was found between the included studies. Since there was significant heterogeneity for IL-10 rs1800871, rs1800872 and rs1800896 polymorphisms under most genetic models, a subgroup analysis was conducted to explore the predefined possible source of heterogeneity. Subgroup analyses showed that ethnicity was significant source of heterogeneity for IL-10 rs1800872 polymorphism (Table 3), but not for rs1800871 and rs1800896 polymorphisms (Tables 2, 4).
Publication Bias
Begger’s funnel plot and Egger’s test were used to assess the publication bias. The standard error of the logarithm of the OR (SE(log[OR])) was plotted against the OR for each study included to this meta-analysis. According to a widely accepted interpretation, when selection bias is present, the plot will become asymmetrical and the meta-analysis’s overall impact will be skewed. The shapes of the Begger’s funnel plots did not show any evidence of publication bias for IL-10 rs1800871 and rs1800872 polymorphisms under all five genetic models and further confirmed by Egger test (Table 2, 3). For IL-10 rs1800896 polymorphism, the results showed that a largely symmetrical distribution of Funnel plots, except for the heterozygote model (GA vs. AA: PBeggs = 0.175 and PEggers = 0.030). Thus, we applied the Duval and Tweedie non-parametric ‘‘trim and fill’’ method to the publication bias (Figure 3). The results showed that the current meta-analysis with and without ‘‘trim and fill’’ did not draw different results, indicating that our results were statistically reliable. Overall, the results suggest this meta-analysis is not affected by publication biases.
Figure 3.
Begg’s Funnel Plots of IL-10 rs1800896 Polymorphism and Lung Cancer Risk for Publication bias Test under the Heterozygote Model (GA vs. AA). Before (blue) and after (red) ‘’Trim-and-Fill’’ method
Discussion
The molecular basis of lung cancer is the gradual accumulation of genetic and epigenetic changes in the cell nucleus [67]. Mutations are an inherent feature of lung cancer development, and their detection has significance in both the diagnostic and treatment stages of disease. To our best knowledge, several epidemiological studies have been performed to examine the association of IL-10 polymorphisms with susceptibility to lung cancer, but their analysis is not comprehensive enough.
Previously, some meta-analyses have analyzed the association of IL-10 gene polymorphisms and risk of lung cancer, but their analysis is not comprehensive enough. Because there are few studies included and the subgroup analyses is not accurate enough in their articles. The present meta-analysis was performed to examine the association of IL-10 rs1800871 (-819C>T), rs1800872 (-592C>A) and rs1800896 (-1082A>G) polymorphisms with risk of lung cancer in different ethnic groups. Our pooled data indicated that IL-10 -592A>C polymorphism was significantly associated with lung cancer risk under four genetic models, i.e., allele (CT vs. TT: OR= 1.17, 95% CI 1.01-1.35, p=0.02), homozygote (CC vs. AA: OR= 1.64, 95% CI 1.29-2.02, p≤0.001), heterozygote (CA vs. AA: OR= 1.26, 95% CI 1.06-1.50, p≤0.001), and dominant (CC+CA vs. AA: OR= 1.31, 95% CI 1.11-1.54, p=0.001). Moreover, our subgroup analysis revealed that this polymorphism was associated with lung cancer among Asians and Caucasians. However, there was no a significant association between the 819T>C and -1082A>G polymorphisms and lung cancer risk. Recently, Ding et al., in a meta-analysis evaluated the association of 11 variants at multiple interleukin including IL-1β, IL-4, IL-6, IL-8 and IL-10 and IL proteins (IL-6, IL-10) relate with risk of lung cancer from 43 articles. Their pooled data showed that the IL-1β rs16944 and IL-10 rs1800872 decreased while IL-10 rs1800896 increased lung cancer risks. In 2020, Gao et al., in a meta-analysis examined the association between interleukin polymorphisms and lung cancer. Their pooled data showed that there was no significant association in distribution of IL-4 rs2070874, IL-6 rs1800795, IL-6 rs1800796, IL-8 rs4073, IL-10 rs1800871, and IL-10 rs1800896 polymorphisms among lung cancer patients and controls. However, their subgroup analysis showed that IL-4 rs2243250 might influence predisposition to lung cancer in Asians, whereas IL-10 rs1800872 polymorphism might influence predisposition to in Caucasians. Yu et al., in a meta-analysis based on 73 studies with 15,942 cancer cases and 22,336 controls evaluated the association between the IL-10 -819C>T polymorphism and cancer risk. Their pooled results showed that this variant was not significantly associated with cancer risk in overall. Their stratified analysis showed that IL-10 -819C>T polymorphism was not significantly associated with breast cancer, colorectal cancer, lung cancer, hepatocellular carcinoma, prostate cancer, lymphoma, or melanoma. The heterozygous variant (CT) and the dominant model (TT/CT vs. CC) were associated with an increased risk for cervical and ovarian cancer [68]. In 2012, Peng et al., in work based on 20 studies involving 6,467 cases and 8,320 controls evaluated the effects of eight polymorphisms including TNF-α 308G>A, IL-6 174G>C, IL-1β 31T>C, IL-1β 511C>T, COX-2 8473T>C, IL-10 -1082G>A, IL-10 -819C>T, and IL-10 -592C>A with susceptibility to lung cancer. Their results revealed that the IL-10 rs1800871, rs1800872 and rs1800896 polymorphisms might be risk factors for lung cancer. TNF-α -308G>A, IL-6 -174G>C, IL-1β 31 T>C, IL-1β -511C>T, COX-2 -8473T>C polymorphisms were not detected to be related to the risk for lung cancer [69].
The heterogeneity and publication bias are of importance which may affect the results of meta-analysis [44, 70, 42, 71, 72]. In the current meta-analysis, a significant heterogeneity existed for -819T>C and -1082A>G polymorphisms under almost genetic models in overall, but not for IL-10 -592A>C. After subgroup analyses by ethnicity, the heterogeneity was not decreased by ethnicity, suggesting that other factors such as gene-environment factors or histological type cause the heterogeneity. In the meta-analysis, publication bias was analyzed by Begg’s funnel plots and the Egger’s test and no significant publication bias was detected, suggesting the reliability of our results [73-75]. Our results showed a publication bias for IL-10 -1082A>G polymorphism under the heterozygote model. However, the ‘‘trim and fill’’ method results did not draw different results, indicating that the results were statistically reliable. In summary, a significant heterogeneity among studies on the association between IL-10 -819T>C and -1082A>G polymorphisms and lung cancer risk in overall population and by ethnicity was observed. However, the source of heterogeneity was not found in the meta-regression analysis, but the sensitivity analysis confirmed a robust association in this study.
Furthermore, the IL-10 -592A>C polymorphism was sensitive to lung cancer susceptibility, and ethnic subgroup analysis obtained from our pooled data indicated that this polymorphism might be a promising biomarker in Caucasian and Asian populations. Nevertheless, there were still some limitations that need to be addressed in this meta-analysis. First, the number of studies for each IL-10 polymorphisms and in the different ethnicity included was not abundant. The difference between ethnicities was smaller due to the limited number of studies included. Thus, whether the association between the IL-10 polymorphisms and risk of lung cancer is dependent on ethnicity remains a matter of debate and more independent studies were needed to evaluate our results. Second, the effects of gender, age, smoking status, lifestyle, and other environmental factors on risk of lung cancer were not considered in the current meta-analysis due to the limitations or unavailable data. Moreover, the genotyping methods for IL-10 polymorphisms genotyping were also inconsistent; all methods were based on PCR-RFLP, PCR-SSP, and each method had its own merits and limitations, so more appropriate methods and guidelines for genotyping required to be discussed. Third, there was clear heterogeneity for association between IL-10 -819T>C and -1082A>G polymorphisms and the occurrence of lung cancer. The final pooled samples included Caucasian and Asian populations. The source of heterogeneity might be that the different ethnicities contained various genetic backgrounds. Fourth, we only selected eligible articles from those previously published, so some relevant unpublished works might be missed, generating certain publication bias, though not detected even with funnel plot or Egger test. Finally, this study did not reveal gene environment and gene-gene interactions, due to the original information of the included studies was not sufficient. Moreover, in this work, just three polymorphisms in the IL-10 gene were analyzed, and information on these particular polymorphisms was limited. Many polymorphic loci have been reported to be involved in the etiology of lung cancer. The occurrence of lung cancer is usually thought to involve multiple genes and their interactions.
Collectively, our findings suggest that IL-10 rs1800871, rs1800872 and rs1800896 polymorphisms might not be risk factor for lung cancer in overall population. However, IL-10 rs1800872 polymorphism was associated with lung cancer risk in Asians and Caucasians. Nevertheless, future research on the subject with greater methodological rigor and sample sizes is mandatory to clarify the role of IL-10 the rs1800871, rs1800872 and rs1800896 polymorphisms and its genetic profiles on risk of lung cancer.
Author Contribution Statement
All authors contributed equally in this study.
Acknowledgements
None.
References
- 1.Mehrabi N, Moshtaghioun SM, Neamatzadeh H. Novel mutations of the chrna3 gene in non-small cell lung cancer in an iranian population. Asian Pac J Cancer Prev. 2017;18(1):253–5. doi: 10.22034/APJCP.2017.18.1.253. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Jafari-Nedooshan J, Moghimi M, Zare M, Heiranizadeh N, Morovati-Sharifabad M, Akbarian-Bafghi MJ, et al. Association of promoter region polymorphisms of il-10 gene with susceptibility to lung cancer: Systematic review and meta-analysis. Asian Pac J Cancer Prev. 2019;20(7):1951–7. doi: 10.31557/APJCP.2019.20.7.1951. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Jafari M, Dastgheib SA, Ferdosian F, Mirjalili H, Aarafi H, Noorishadkam M, et al. Proportion of hematological cancer patients with sars-cov-2 infection during the covid-19 pandemic: A systematic review and meta-analysis. Hematol Transfus Cell Ther. 2022;44(2):225–34. doi: 10.1016/j.htct.2021.09.020. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Peravali M, Joshi I, Ahn J, Kim C. A systematic review and meta-analysis of clinical characteristics and outcomes in patients with lung cancer with coronavirus disease 2019. JTO Clin Res Rep. 2021;2(3):100141. doi: 10.1016/j.jtocrr.2020.100141. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Asadian F, Nataj MG, Neamatzadeh H, MİRjalİLİ H, VakİLİ M, DastgİRİ AS, et al. A meta-analysis for prevalence of lung cancer patients with sars-cov-2 infection during the covid-19 pandemic. Eurasian Journal of Medicine and Oncology. 2022;6(1):73–82. [Google Scholar]
- 6.Thandra KC, Barsouk A, Saginala K, Aluru JS, Barsouk A. Epidemiology of lung cancer. Contemp Oncol (Pozn) 2021;25(1):45–52. doi: 10.5114/wo.2021.103829. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. doi: 10.3322/caac.21660. [DOI] [PubMed] [Google Scholar]
- 8.Asgari M, Firouzi F, Abolhasani M, Bahadoram M, Barahman M, Madjd Z, et al. The association of p53, ck29, and fgfr3 overexpression with the characteristics of urothelial cell carcinoma of the bladder. Asian Pac J Cancer Prev. 2023;24(9):3125–31. doi: 10.31557/APJCP.2023.24.9.3125. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Abbaspour S, Abdollahi H, Arabalibeik H, Barahman M, Arefpour AM, Fadavi P, et al. Endorectal ultrasound radiomics in locally advanced rectal cancer patients: Despeckling and radiotherapy response prediction using machine learning. Abdom Radiol (NY) 2022;47(11):3645–59. doi: 10.1007/s00261-022-03625-y. [DOI] [PubMed] [Google Scholar]
- 10.Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: Epidemiology, etiology, and prevention. Clin Chest Med. 2011;32(4):605–44. doi: 10.1016/j.ccm.2011.09.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Babakhanzadeh E, Khodadadian A, Nazari M, Dehghan Tezerjani M, Aghaei SM, Ghasemifar S, et al. Deficient expression of dgcr8 in human testis is related to spermatogenesis dysfunction, especially in meiosis i. Int J Gen Med. 2020;13:185–92. doi: 10.2147/IJGM.S255431. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Raso MG, Bota-Rabassedasm, Wistuba II. Pathology and classification of sclc. Cancers (Basel) 2021;13:4. doi: 10.3390/cancers13040820. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Najminejad H, Farhadihosseinabadi B, Dabaghian M, Dezhkam A, Rigi Yousofabadi E, Najminejad R, et al. Key regulatory mirnas and their interplay with mechanosensing and mechanotransduction signaling pathways in breast cancer progression. Mol Cancer Res. 2020;18(8):1113–28. doi: 10.1158/1541-7786.MCR-19-1229. [DOI] [PubMed] [Google Scholar]
- 14.Bahadoram S, Davoodi M, Hassanzadeh S, Bahadoram M, Barahman M, Mafakher L. Renal cell carcinoma: An overview of the epidemiology, diagnosis, and treatment. G Ital Nefrol. 2022;39:3. [PubMed] [Google Scholar]
- 15.Farshid S, Alijanpour A, Barahman M, Dastgheib SA, Narimani N, Shirinzadeh-Dastgiri Z, et al. Associations of mthfr rs1801133 (677c>t) and rs180113 (1298a>c) polymorphisms with susceptibility to bladder cancer: A systematic review and meta-analysis. Asian Pac J Cancer Prev. 2022;23(5):1465–82. doi: 10.31557/APJCP.2022.23.5.1465. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Kanwal M, Ding XJ, Cao Y. Familial risk for lung cancer. Oncol Lett. 2017;13(2):535–42. doi: 10.3892/ol.2016.5518. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Mazaheri M, Yavari M, Zare Marzouni H, Stufano A, Lovreglio P, S’Amore S, et al. Case report: Mutation in aimp2/p38, the scaffold for the multi-trna synthetase complex, and association with progressive neurodevelopmental disorders. Front Genet. 2022;13:816987. doi: 10.3389/fgene.2022.816987. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Mohiti Ardakani E, Mazaheri M, Ph D, Forouzanfar M, Mojibian M, Jafarinia M. Crucial role of corticotropin-releasing hormone, corticotropin-releasing hormone -binding protein, mir-200c, and mir-181a in preterm delivery: A case-control study. Int J Reprod Biomed. 2023;21(9):715–22. doi: 10.18502/ijrm.v21i9.14398. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Zanetti KA, Wang Z, Aldrich M, Amos CI, Blot WJ, Bowman ED, et al. Genome-wide association study confirms lung cancer susceptibility loci on chromosomes 5p15 and 15q25 in an african-american population. Lung Cancer. 2016;98:33–42. doi: 10.1016/j.lungcan.2016.05.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Razmjoo S, Jazayeri SN, Bahadoram M, Barahman M. A rare case of craniopharyngioma in the temporal lobe. Case Rep Neurol Med. 2017;2017:4973560. doi: 10.1155/2017/4973560. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Moghimi M, Ahrar H, Karimi-Zarchi M, Aghili K, Salari M, Zare-Shehneh M, et al. Association of il-10 rs1800871 and rs1800872 polymorphisms with breast cancer risk: A systematic review and meta-analysis. Asian Pac J Cancer Prev. 2018;19(12):3353–9. doi: 10.31557/APJCP.2018.19.12.3353. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Ferdosian F, Dastgheib SA, Morovati-Sharifabad M, Lookzadeh MH, Noorishadkam M, Mirjalili SR, et al. Cumulative evidence for association between il-10 polymorphisms and kawasaki disease susceptibility: A systematic review and meta-analysis. Fetal Pediatr Pathol. 2021;40(2):153–65. doi: 10.1080/15513815.2019.1686789. [DOI] [PubMed] [Google Scholar]
- 23.Dastgheib SA, Aarafi H, Bahrami R, Safa A, Khosravi-Bonjar A, Hashemzehi A, et al. Association of il-10-1082g>a, -819c>t and -592c>a polymorphisms with susceptibility to asthma in children: A systematic review and meta-analysis. Eur Ann Allergy Clin Immunol. 2022;54(1):4–15. doi: 10.23822/EurAnnACI.1764-1489.219. [DOI] [PubMed] [Google Scholar]
- 24.Abbasi H, Dastgheib SA, Hadadan A, Karimi-Zarchi M, Javaheri A, Meibodi B, et al. Association of endothelial nitric oxide synthase 894g > t polymorphism with preeclampsia risk: A systematic review and meta-analysis based on 35 studies. Fetal Pediatr Pathol. 2021;40(5):455–70. doi: 10.1080/15513815.2019.1710880. [DOI] [PubMed] [Google Scholar]
- 25.Mirjalili SA, Moghimi M, Aghili K, Jafari M, Abolbaghaei SM, Neamatzadeh H, et al. Association of promoter region polymorphisms of interleukin-10 gene with susceptibility to colorectal cancer: A systematic review and meta-analysis. Arq Gastroenterol. 2018;55(3):306–13. doi: 10.1590/S0004-2803.201800000-66. [DOI] [PubMed] [Google Scholar]
- 26.Khodadadian A, Hemmati-Dinarvand M, Kalantary-Charvadeh A, Ghobadi A, Mazaheri M. Candidate biomarkers for parkinson’s disease. Biomed Pharmacother. 2018;104:699–704. doi: 10.1016/j.biopha.2018.05.026. [DOI] [PubMed] [Google Scholar]
- 27.Sheikhpour E, Noorbakhsh P, Foroughi E, Farahnak S, Nasiri R, Neamatzadeh H. A survey on the role of interleukin-10 in breast cancer: A narrative. Rep Biochem Mol Biol. 2018;7(1):30–7. [PMC free article] [PubMed] [Google Scholar]
- 28.Soleimani-Jadidi S, Abbasi H, Javaheri A, Behforouz A, Zanbagh L, Meibodi B, et al. Cumulative evidence for association of il-10 -1082g > a polymorphism with susceptibility to recurrent pregnancy loss: A systematic review and meta-analysis. Fetal Pediatr Pathol. 2021;40(5):471–85. doi: 10.1080/15513815.2020.1716903. [DOI] [PubMed] [Google Scholar]
- 29.Mashhadiabbas F, Dastgheib SA, Hashemzehi A, Bahrololoomi Z, Asadian F, Neamatzadeh H, et al. Association of il-10 -1082a>g, -819c>t, and -592c>a polymorphisms with susceptibility to chronic and aggressive periodontitis: A systematic review and meta-analysis. Inflamm Res. 2021;70(5):509–24. doi: 10.1007/s00011-021-01448-z. [DOI] [PubMed] [Google Scholar]
- 30.Bokaie M, Farajkhoda T, Enjezab B, Heidari P, Karimi Zarchi M. Barriers of child adoption in infertile couples: Iranian’s views. Iran J Reprod Med. 2012;10(5):429–34. [PMC free article] [PubMed] [Google Scholar]
- 31.Doosti M, Bakhshesh M, Zahir ST, Shayestehpour M, Karimi-Zarchi M. Lack of evidence for a relationship between high risk human papillomaviruses and breast cancer in iranian patients. Asian Pac J Cancer Prev. 2016;17(9):4357–61. [PubMed] [Google Scholar]
- 32.Braga M, Lara-Armi FF, Neves JSF, Rocha-Loures MA, Terron-Monich MS, Bahls-Pinto LD, et al. Influence of il10 (rs1800896) polymorphism and tnf-α, il-10, il-17a, and il-17f serum levels in ankylosing spondylitis. Front Immunol. 2021;12:653611. doi: 10.3389/fimmu.2021.653611. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Farbod M, Karimi MZ, Heiranizadeh N, Seifi NS, Akbarian JBM, Jarahzadeh HM, et al. Association of TNF-α -308G>A polymorphism with susceptibility to cervical cancer and breast cancer - a systematic review and meta-analysis. Klin Onkol. 2019;32(3):170–80. doi: 10.14735/amko2019170. [DOI] [PubMed] [Google Scholar]
- 34.Aflatoonian M, Sivandzadeh G, Morovati-Sharifabad M, Mirjalili SR, Akbarian-Bafghi MJ, Neamatzadeh H. Associations of il-6 -174g>c and il-10 -1082a>g polymorphisms with susceptibility to celiac disease: Evidence from a meta-analysis and literature review. Arq Gastroenterol. 2019;56(3):323–8. doi: 10.1590/S0004-2803.201900000-60. [DOI] [PubMed] [Google Scholar]
- 35.Salimi E, Karimi-Zarchi M, Dastgheib SA, Abbasi H, Tabatabaiee RS, Hadadan A, et al. Association of promoter region polymorphisms of il-6 and il-18 genes with risk of recurrent pregnancy loss: A systematic review and meta-analysis. Fetal Pediatr Pathol. 2020;39(4):346–59. doi: 10.1080/15513815.2019.1652379. [DOI] [PubMed] [Google Scholar]
- 36.Asadollahi S, Mazaheri MN, Karimi-Zarchi M, Fesahat, Farzaneh The relationship of foxr2 gene expression profile with epithelial-mesenchymal transition related markers in epithelial ovarian cancer. Klin Onkol. 2020;33(3):201–7. doi: 10.14735/amko2020201. [DOI] [PubMed] [Google Scholar]
- 37.Esmaeili R, Mohammadi S, Jafarbeik-Iravani N, Yadegari F, Olfatbakhsh A, Mazaheri M, et al. Expression of scube2 and bcl2 predicts favorable response in erα positive breast cancer. Arch Iran Med. 2021;24(3):209–17. doi: 10.34172/aim.2021.32. [DOI] [PubMed] [Google Scholar]
- 38.Zhang YM, Mao YM, Sun YX. Genetic polymorphisms of il-6 and il-10 genes correlate with lung cancer in never-smoking han population in china. Int J Clin Exp Med. 2015;8(1):1051–8. [PMC free article] [PubMed] [Google Scholar]
- 39.Hsia TC, Chang WS, Liang SJ, Chen WC, Tu CY, Chen HJ, et al. Interleukin-10 (il-10) promoter genotypes are associated with lung cancer risk in taiwan males and smokers. Anticancer Res. 2014;34(12):7039–44. [PubMed] [Google Scholar]
- 40.Mirjalili H, Dastgheib SA, Shaker SH, Bahrami R, Mazaheri M, Sadr-Bafghi SMH, et al. Proportion and mortality of iranian diabetes mellitus, chronic kidney disease, hypertension and cardiovascular disease patients with covid-19: A meta-analysis. J Diabetes Metab Disord. 2021;20(1):905–17. doi: 10.1007/s40200-021-00768-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Antikchi MH, Neamatzadeh H, Ghelmani Y, Jafari-Nedooshan J, Dastgheib SA, Kargar S, et al. The risk and prevalence of covid-19 infection in colorectal cancer patients: A systematic review and meta-analysis. J Gastrointest Cancer. 2021;52(1):73–9. doi: 10.1007/s12029-020-00528-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Aslebahar F, Neamatzadeh H, Meibodi B, Karimi-Zarchi M, Tabatabaei RS, Noori-Shadkam M, et al. Association of tumor necrosis factor-α (tnf-α) -308g>a and -238g>a polymorphisms with recurrent pregnancy loss risk: A meta-analysis. Int J Fertil Steril. 2019;12(4):284–92. doi: 10.22074/ijfs.2019.5454. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Farajkhoda T, Khoshbin A, Enjezab B, Bokaei M, Karimi Zarchi M. Assessment of two emergency contraceptive regimens in iran: Levonorgestrel versus the yuzpe. Niger J Clin Pract. 2009;12(4):450–2. [PubMed] [Google Scholar]
- 44.Ghaemmaghami F, Karimi Zarchi M, Mousavi A. Surgical management of primary vulvar lymphangioma circumscriptum and postradiation: Case series and review of literature. J Minim Invasive Gynecol. 2008;15(2):205–8. doi: 10.1016/j.jmig.2007.09.005. [DOI] [PubMed] [Google Scholar]
- 45.Karimi-Zarchi M, Abbasi H, Javaheri A, Hadadan A, Meibodi B, Tabatabaei RS, et al. Association of il-12b rs3212227 and il-6 rs1800795 polymorphisms with susceptibility to cervical cancer: A systematic review and meta-analysis. Asian Pac J Cancer Prev. 2020;21(5):1197–206. doi: 10.31557/APJCP.2020.21.5.1197. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Ghorbani S, Rezapour A, Eisavi M, Barahman M, Bagheri Faradonbeh S. Cost-benefit analysis of breast cancer screening with digital mammography: A systematic review. Med J Islam Repub Iran. 2023;37:89. doi: 10.47176/mjiri.37.89. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Davari HM, Rahim MM, Ershadi RM, Rafieian SM, Mardani PM, Vakili MM, et al. First iranian experience of the minimally invasive nuss procedure for pectus excavatum repair: A case series and literature review. Iran J Med Sci. 2018;43(5):554–9. [PMC free article] [PubMed] [Google Scholar]
- 48.Bahrami R, Dastgheib SA, Niktabar SM, Amooee A, Lookzadeh MH, Mirjalili SR, et al. Association of bmp4 rs17563 polymorphism with nonsyndromic cleft lip with or without cleft palate risk: Literature review and comprehensive meta-analysis. Fetal Pediatr Pathol. 2021;40(4):305–19. doi: 10.1080/15513815.2019.1707916. [DOI] [PubMed] [Google Scholar]
- 49.Shirinzadeh-Dastgiri A, Saberi A, Vakili M, Marashi SM. 21-year-old female with pneumothorax and massive air leak following blunt trauma; a photo quiz. Arch Acad Emerg Med. 2022;10(1):e24. doi: 10.22037/aaem.v10i1.1513. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Mousavi A, Karimi Zarchi M, Gilani MM, Behtash N, Ghaemmaghami F, Shams M, et al. Radical hysterectomy in the elderly. World J Surg Oncol. 2008;6:38. doi: 10.1186/1477-7819-6-38. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Karimi-Zarchi M, Schwartz DA, Bahrami R, Dastgheib SA, Javaheri A, Tabatabaiee RS, et al. A meta-analysis for the risk and prevalence of preeclampsia among pregnant women with covid-19. Turk J Obstet Gynecol. 2021;18(3):224–35. doi: 10.4274/tjod.galenos.2021.66750. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Vakili J, Samadi N, Dargah M, Isazadehfar K, Kabar S, Zade A, et al. Comparative analysis of the effects of vasopersin and norepinephrine on the renal function in patients undergoing cabg. Iran Red Crescent Med J. 2018 [Google Scholar]
- 53.Razmpoosh E, Safi S, Abdollahi N, Nadjarzadeh A, Nazari M, Fallahzadeh H, et al. The effect of nigella sativa on the measures of liver and kidney parameters: A systematic review and meta-analysis of randomized-controlled trials. Pharmacol Res. 2020;156:104767. doi: 10.1016/j.phrs.2020.104767. [DOI] [PubMed] [Google Scholar]
- 54.Amini K, Vakili Ogharood M, Davari M, Ershadifard S, Asadi H. A case of a fractured fragment of tracheostomy tube entering the left bronchus: A case report. J Babol Univ Med Sci. 2021;23(1):393–7. [Google Scholar]
- 55.Bahrami R, Schwartz DA, Karimi-Zarchi M, Javaheri A, Dastgheib SA, Ferdosian F, et al. Meta-analysis of the frequency of intrauterine growth restriction and preterm premature rupture of the membranes in pregnant women with covid-19. Turk J Obstet Gynecol. 2021;18(3):236–44. doi: 10.4274/tjod.galenos.2021.74829. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Vakili Ojarood M, Khanghah AS, Belalzadeh M. Gangrenous ischemic colitis due to acute promyelocytic leukaemia, and myelofibrosis in a 62-year-old man suffering from esrd; case report. Int J Surg Case Rep. 2021;89:106663. doi: 10.1016/j.ijscr.2021.106663. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Seifart C, Plagens A, Dempfle A, Clostermann U, Vogelmeier C, von Wichert P, et al. Tnf-alpha, tnf-beta, il-6, and il-10 polymorphisms in patients with lung cancer. Dis Markers. 2005;21(3):157–65. doi: 10.1155/2005/707131. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Shih CM, Lee YL, Chiou HL, Hsu WF, Chen WE, Chou MC, et al. The involvement of genetic polymorphism of il-10 promoter in non-small cell lung cancer. Lung Cancer. 2005;50(3):291–7. doi: 10.1016/j.lungcan.2005.07.007. [DOI] [PubMed] [Google Scholar]
- 59.Vogel U, Christensen J, Dybdahl M, Friis S, Hansen RD, Wallin H, et al. Prospective study of interaction between alcohol, nsaid use and polymorphisms in genes involved in the inflammatory response in relation to risk of colorectal cancer. Mutat Res. 2007;624(1-2):88–100. doi: 10.1016/j.mrfmmm.2007.04.006. [DOI] [PubMed] [Google Scholar]
- 60.Colakogullari M, Ulukaya E, Yilmaztepe Oral A, Aymak F, Basturk B, Ursavas A, et al. The involvement of il-10, il-6, ifn-gamma, tnf-alpha and tgf-beta gene polymorphisms among turkish lung cancer patients. Cell Biochem Funct. 2008;26(3):283–90. doi: 10.1002/cbf.1419. [DOI] [PubMed] [Google Scholar]
- 61.Hao M, Wang W, Lu Y. Association of genetic polymorphism within promoter region of tnf-α, il-1β and il-10 with the susceptibility to lung cancer. Huan Jing Yu Zhi Ye Yi Xue. 2009;26(26):24–7. [Google Scholar]
- 62.Liang H, Zhao-Ran F, Xi-Ming Q. Relationship between the genetic polymorphism in interleukin-10-592c/a and susceptibility to non-small cell lung cancer. Chin J Integr Med. 2011;21:189–93. [Google Scholar]
- 63.Hart K, Landvik NE, Lind H, Skaug V, Haugen A, Zienolddiny S. A combination of functional polymorphisms in the casp8, mmp1, il10 and seps1 genes affects risk of non-small cell lung cancer. Lung cancer. 2011;71 2:123–9. doi: 10.1016/j.lungcan.2010.04.016. [DOI] [PubMed] [Google Scholar]
- 64.Peddireddy V, Badabagni SP, Sulthana S, Kolla VK, Gundimeda SD, Mundluru H. Association of tnfα(-308), ifnγ(+874), and il10(-1082) gene polymorphisms and the risk of non-small cell lung cancer in the population of the south indian state of telangana. Int J Clin Oncol. 2016;21(5):843–52. doi: 10.1007/s10147-016-0972-2. [DOI] [PubMed] [Google Scholar]
- 65.Eaton KD, Romine PE, Goodman GE, Thornquist MD, Barnett MJ, Petersdorf EW. Inflammatory gene polymorphisms in lung cancer susceptibility. J Thorac Oncol. 2018;13(5):649–59. doi: 10.1016/j.jtho.2018.01.022. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66.Nong J, Gong Y, Guan Y, Yi X, Yi Y, Chang L, et al. Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer. Nat Commun. 2018;9(1):3114. doi: 10.1038/s41467-018-05327-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67.Mojtabavi Naeini M, Tavassoli M, Ghaedi K. Systematic bioinformatic approaches reveal novel gene expression signatures associated with acquired resistance to egfr targeted therapy in lung cancer. Gene. 2018;667:62–9. doi: 10.1016/j.gene.2018.04.077. [DOI] [PubMed] [Google Scholar]
- 68.Yu Z, Liu Q, Huang C, Wu M, Li G. The interleukin 10 -819c/t polymorphism and cancer risk: A huge review and meta-analysis of 73 studies including 15,942 cases and 22,336 controls. Omics. 2013;17(4):200–14. doi: 10.1089/omi.2012.0089. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 69.Peng WJ, He Q, Yang JX, Wang BX, Lu MM, Wang S, et al. Meta-analysis of association between cytokine gene polymorphisms and lung cancer risk. Mol Biol Rep. 2012;39(5):5187–94. doi: 10.1007/s11033-011-1315-z. [DOI] [PubMed] [Google Scholar]
- 70.Sohrevardi SM, Nosouhi F, Hossein Khalilzade S, Kafaie P, Karimi-Zarchi M, Halvaei I, et al. Evaluating the effect of insulin sensitizers metformin and pioglitazone alone and in combination on women with polycystic ovary syndrome: An rct. Int J Reprod Biomed. 2016;14(12):743–54. [PMC free article] [PubMed] [Google Scholar]
- 71.Sobhan MR, Mahdinezhad-Yazdi M, Dastgheib SA, Jafari M, Raee-Ezzabadi A, Neamatzadeh H. Association of esrα xbai a > g, esrα pvuii t > c and esrβ alwni t > c polymorphisms with the risk of developing adolescent idiopathic scoliosis: A systematic review and genetic meta-analysis. Rev Bras Ortop (Sao Paulo) 2020;55(1):8–16. doi: 10.1016/j.rboe.2018.03.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 72.Abbaspour S, Barahman M, Abdollahi H, Arabalibeik H, Hajainfar G, Babaei M, et al. Multimodality radiomics prediction of radiotherapy-induced the early proctitis and cystitis in rectal cancer patients: A machine learning study. Biomed Phys Eng Express. 2023;10:1. doi: 10.1088/2057-1976/ad0f3e. [DOI] [PubMed] [Google Scholar]
- 73.Alemrajabi M, Khavanin Zadeh M, Hemmati N, Banivaheb B, Alemrajabi F, Jahanian S, et al. Inferior part of rectus abdominis muscle flap outcomes after abdominoperineal resection: A case series pilot study. World J Plast Surg. 2021;10(3):104–10. doi: 10.29252/wjps.10.3.104. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 74.Safi S, Razmpoosh E, Fallahzadeh H, Mazaheri M, Abdollahi N, Nazari M, et al. The effect of nigella sativa on appetite, anthropometric and body composition indices among overweight and obese women: A crossover, double-blind, placebo-controlled, randomized clinical trial. Complement Ther Med. 2021;57:102653. doi: 10.1016/j.ctim.2020.102653. [DOI] [PubMed] [Google Scholar]
- 75.Novin K, Fadavi P, Mortazavi N, Sanei M, Khoshbakht Ahmadi H, Barahman M, et al. Neutrophil-to-lymphocyte ratio (nlr) as a poor predictive biomarker for pathological response to neoadjuvant chemoradiation in locally advanced rectal cancer: A prospective study. Asian Pac J Cancer Prev. 2023;24(1):61–7. doi: 10.31557/APJCP.2023.24.1.61. [DOI] [PMC free article] [PubMed] [Google Scholar]



